Genomic CpG enrichment of oncolytic parvoviruses as a potent anticancer vaccination strategy for the treatment of pancreatic adenocarcinoma

Journal of Vaccines and Vaccination

Volumn 5, Issue 3, 2014, Pages

  Grekova, Svitlana P ^a   Aprahamian, Marc ^b   Giese, Nathalia A ^c   Bour, Gaetan ^b   Giese, Thomas ^d   Grewenig, Annabel ^a   Leuchs, Barbara ^a   Hörlein, Rita ^a   Heller, Anette ^c   Angelova, Assia L ^a   Rommelaere, Jean ^a   Raykov, Zahari ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Institut de Recherche Contre les Cancers de l'Appareil Digestif   (France)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CpG motifs; Immune respons; Immunomodulation; Pancreatic cancer; Parvovirus H 1PV; Ssystemic application

Indexed keywords

EID: 84902603199     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000227     Document Type: Article

References (20)

1. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, et al. (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 21: 185-195.
2. Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, et al. (2012) Phase I/IIa study of intratumoral/intracerebral or intravenous/ intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastomamultiforme: ParvOryx01 protocol. BMC Cancer 12: 99.
3. Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, et al. (2011) Interferon gamma improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol The 12: 888-895.
4. Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J (2008) Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer 122: 2880-2884.
5. Raykov Z, Grekova SP, Hörlein R, Leuchs B, Giese T, et al. (2013) TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. PLoS One 8: e55086.
6. Morales O, Richard A, Martin N, Mrizak D, Sénéchal M, et al. (2012) Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus. PLoS One 7: e32197.
7. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, et al. (2005) Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and crosspresentation by dendritic cells. Hum gene ther 16: 996-1005.
8. Bhat R, Dempe S, Dinsart C, Rommelaere J (2011) Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer 128: 908-919.
9. Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, et al. (2010) Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer BiolTher 10: 1280-1289.
10. Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, et al. (2007) Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 17: 1493-1499.
11. Raykov Z, Savelyeva L, Balboni G, Giese T, Rommelaere J, et al. (2005) lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol 79: 3517-3524.
12. Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, et al. (2012) Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Science translational medicine 4: 138ra177.
13. Grekova SP, Raykov Z, Zawatzky R, Rommelaere J, Koch U (2012) Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Ther 19: 468-475.
14. Schmitz-Winnenthal FH, Escobedo LV, Beckhove P, Schirrmacher V, Bucur M, et al. (2006) Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. International journal of oncology 28: 1419-1428.
15. Kroemer GL, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72.
16. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, et al. (2009) Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 15: 511-519.
17. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, et al. (2008) Purging metastases in lymphoid organs using a combination of antigennonspecific adoptive T cell therapy, oncolyticvirotherapy and immunotherapy. Nature medicine 14: 37-44.
18. Raykov Z, Balboni G, Aprahamian M, Rommelaere J (2004) Carrier cellmediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 109: 742-749.
19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
20. Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, et al. (2013) Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO molecular medicine 5: 1537-1555.